GluSense said yesterday that it received a $2 million grant from the Juvenile Diabetes Research Foundation’s T1D fund for the company’s injectable glucose sensor.
Israel-based GluSense, part of Rainbow Medical, is developing the Glyde continuous glucose monitor for patients with Type I diabetes. The device is injected under the skin and lasts for 1 year, according to the company, sending continuous glucose measurements wirelessly to a wearable device.
Get the full story at our sister site, Drug Delivery Business News.
The post JDRF backs GluSense with $2m grant appeared first on MassDevice.
from MassDevice http://ift.tt/2kXc9rq
Cap comentari:
Publica un comentari a l'entrada